Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

Up to 60 myeloma bone marrow samples from Myeloma patients and 10 bone marrow samples from other haematological malignancy samples (Acute leukaemia's) at Diagnosis and Relapse will be tested.

Patients attending haematology clinics at New Cross Hospital will be reviewed for eligibility of the study by the clinician and if they meet the recruitment criteria, they will be approached to participate at clinic.

After informed consent, participants will be asked to donate an additional 2-3ml sample of bone marrow in a single aliquot for the purpose of this study whilst undergoing a bone marrow aspirate as part of their routine clinical care at diagnosis and relapse.The single aliquot will be sent to the University of Wolverhampton for analysis.

Specific clincial data will be collected at the time of diagnosis and relapse:

• Diagnosis
• Date diagnosed
• Disease stage
• Relapse status
• Age
• Sex
• Previous treatments
• Date of marrow sample
• Marrow trephine
• Marrow liquid The clinical data set will remain at The Royal Wolverhampton NHS Trust whilst analysis of the samples takes place. Once the samples have been analysed, the clinical data will then be released to determine relapsed or refractory disease and correlation with the in vitro data.

Inclusion criteria

• Patients diagnosed with haematological malignancy - either myeloma or acute leukaemia
• Patients must be 18 years or over
• Patients must be willing and able to give informed consent

Exclusion criteria

• Pregnant patients will not be entered